Allergology International最新文献

{"title":"Association between low serum testosterone level and severe asthma among elderly women","authors":"Kai Ryu ,&nbsp;Yuma Fukutomi ,&nbsp;Eiji Nakatani ,&nbsp;Yosuke Kamide ,&nbsp;Kiyoshi Sekiya ,&nbsp;Takeo Ishikawa ,&nbsp;Takanori Numata ,&nbsp;Jun Araya ,&nbsp;Kazuyoshi Kuwano ,&nbsp;Masami Taniguchi ,&nbsp;Hiroaki Masuzaki","doi":"10.1016/j.alit.2024.12.008","DOIUrl":"10.1016/j.alit.2024.12.008","url":null,"abstract":"<div><h3>Background</h3><div>Elderly asthma has distinct pathophysiologic and phenotypic characteristics compared with asthma in younger patients. However, a potential relationship between sex hormones and the severity of asthma remains unknown in the elderly population. The aim of the present study was to elucidate the relationship between the level of circulating free testosterone and severity of asthma among Japanese with elderly asthma.</div></div><div><h3>Methods</h3><div>The level of free testosterone was measured using sera from elderly patients with asthma aged ≥60 years (n = 192), and its association with the severity of asthma was examined after stratification by sex.</div></div><div><h3>Results</h3><div>Based on previous literature and our preliminary analysis showing that current oral corticosteroid (OCS) use might be a risk factor for a lower free testosterone level regardless of severity of asthma, analyzed patients were limited to those who were not currently using OCS (n = 164). Regarding elderly men who were not currently using OCS (n = 62), there was no significant association between free testosterone level and severity of asthma. However, in female counterparts (n = 102), a low free testosterone level was significantly associated with severe asthma even after adjustment for age (p for trend, 0.03).</div></div><div><h3>Conclusions</h3><div>The present study showed a significant association between the serum free testosterone level and severity of asthma among elderly women who were not currently using OCS. Although the causal relationship is unclear, this finding may provide a clue to understand the sex difference in the mechanisms of severe asthma in elderly populations.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 3","pages":"Pages 453-460"},"PeriodicalIF":6.2,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The immune network across organs","authors":"Hideaki Morita (Associate Editor, Allergology International)","doi":"10.1016/j.alit.2025.03.001","DOIUrl":"10.1016/j.alit.2025.03.001","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 2","pages":"Pages 175-176"},"PeriodicalIF":6.2,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143715757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple at-risk groups have lower lung function during the grass pollen season","authors":"N. Sabrina Idrose ,&nbsp;Don Vicendese ,&nbsp;E. Haydn Walters ,&nbsp;Jennifer L. Perret ,&nbsp;Jennifer J. Koplin ,&nbsp;Jo A. Douglass ,&nbsp;Rachel CA. Tham ,&nbsp;Peter Frith ,&nbsp;Dinh S. Bui ,&nbsp;Adrian J. Lowe ,&nbsp;Michael J. Abramson ,&nbsp;Gayan Bowatte ,&nbsp;Bircan Erbas ,&nbsp;Luke D. Knibbs ,&nbsp;Chamara Senaratna ,&nbsp;Caroline J. Lodge ,&nbsp;Shyamali C. Dharmage","doi":"10.1016/j.alit.2025.02.003","DOIUrl":"10.1016/j.alit.2025.02.003","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 3","pages":"Pages 482-484"},"PeriodicalIF":6.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143659330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The roles of bitter and sweet taste receptors in food allergy: Where are we now?","authors":"Mo Xian ,&nbsp;Anish R. Maskey ,&nbsp;Daniel Kopulos ,&nbsp;Xiu-Min Li","doi":"10.1016/j.alit.2025.01.005","DOIUrl":"10.1016/j.alit.2025.01.005","url":null,"abstract":"<div><div>Food allergy (FA) is a growing global concern, which contributes significantly to anaphylaxis and severe allergic reactions. Despite advancements in treatments like allergen immunotherapy and biologics, current approaches have notable limitations and there is a pressing need for new therapeutic strategies. Recent research into taste receptors has unveiled their potential role in FA, offering fresh perspectives for understanding and managing this condition. Taste receptors, particularly type 1 taste receptors (TAS1Rs/T1Rs, sweet taste receptors) and type 2 taste receptors (TAS2Rs/T2Rs, bitter taste receptors), are distributed not only in the oral cavity but also in various extra-oral tissues, and their interactions with immune responses are increasingly recognized. This review highlights the connections between taste receptors and FA, exploring how taste receptor mechanisms might contribute to FA pathogenesis and treatment. Taste receptors, especially TAS2Rs, which include multiple subtypes with varying ligand specificities, have been implicated in modulating allergic responses and could serve as targets for novel FA therapies. Additionally, compounds such as bitter agents and sweeteners that interact with taste receptors show promise in influencing FA outcomes. This review emphasizes the need for further research into the mechanisms of taste receptor involvement in FA and suggests that targeting these receptors could provide new avenues for therapeutic intervention in the future.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 3","pages":"Pages 386-396"},"PeriodicalIF":6.2,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship of polyunsaturated and monounsaturated fatty acids intake and serum concentrations on inhalant allergen sensitization and allergic rhinitis development","authors":"Chihiro Nakamura ,&nbsp;Atsushi Matsubara ,&nbsp;Ayami Nomura ,&nbsp;Junko Takahata ,&nbsp;Kaori Sawada ,&nbsp;Shigeyuki Nakaji","doi":"10.1016/j.alit.2024.12.009","DOIUrl":"10.1016/j.alit.2024.12.009","url":null,"abstract":"<div><h3>Background</h3><div>The increasing prevalence of allergic rhinitis may be attributed to lifestyle changes such as dietary habits. Regarding dietary factors, n-3 and n-6 polyunsaturated fatty acids (PUFAs) are considered to be involved in the pathogenesis. Therefore, we examined whether the intake and serum concentrations of fatty acids affect inhaled allergen sensitization and the development of allergic rhinitis.</div></div><div><h3>Methods</h3><div>In total, 571 participants (20–69 years) from the Iwaki Health Promotion Project, a community-based project in 2022, were surveyed. Based on the results of PUFA intake and serum fatty acid concentrations obtained using a self-administered diet-history questionnaire, we examined whether n-3 or n-6 PUFAs were involved in reducing or increasing the risk of sensitization, respectively, and developing the disease. We also analyzed whether monounsaturated fatty acids—palmitoleic acid and oleic acid—were risk factors for sensitization and development. Univariate dietary intake, serum concentration, and logistic regression analyses were performed to identify the risk factors.</div></div><div><h3>Results</h3><div>Our study revealed that higher serum concentrations of n-3 PUFAs were associated with a decreased risk of developing rhinitis, but had no effect on allergen sensitization in younger age group &lt;50 years. Furthermore, palmitoleic acid had increased sensitization, and oleic acid may also increase the risk of the allergen sensitization.</div></div><div><h3>Conclusions</h3><div>n-3 PUFAs may reduce the risk of developing allergic rhinitis. Notably, palmitoleic acid may be a new risk factor that increases the risk of inhalant allergen sensitization and allergic rhinitis. These findings are significant in understanding the role of dietary factors in allergic rhinitis.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 3","pages":"Pages 461-467"},"PeriodicalIF":6.2,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2024","authors":"Hidehisa Saeki ,&nbsp;Yukihiro Ohya ,&nbsp;Hirokazu Arakawa ,&nbsp;Susumu Ichiyama ,&nbsp;Toshio Katsunuma ,&nbsp;Norito Katoh ,&nbsp;Akio Tanaka ,&nbsp;Hideaki Tanizaki ,&nbsp;Yuichiro Tsunemi ,&nbsp;Takeshi Nakahara ,&nbsp;Mizuho Nagao ,&nbsp;Masami Narita ,&nbsp;Michihiro Hide ,&nbsp;Takao Fujisawa ,&nbsp;Masaki Futamura ,&nbsp;Koji Masuda ,&nbsp;Tomoyo Matsubara ,&nbsp;Hiroyuki Murota ,&nbsp;Kiwako Yamamoto-Hanada ,&nbsp;Junichi Furuta","doi":"10.1016/j.alit.2025.01.003","DOIUrl":"10.1016/j.alit.2025.01.003","url":null,"abstract":"<div><div>This is an abridged edition of English version of the Clinical Practice Guidelines for the Management of Atopic Dermatitis 2024. Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. A crucial aspect of AD treatment is the prompt induction of remission via the suppression of existing skin inflammation and pruritus. To achieve this, topical anti-inflammatory drugs such as topical corticosteroids, tacrolimus ointment, delgocitinib ointment, and difamilast ointment have been used. However, the following treatments should be considered in addition to topical therapy for patients with refractory moderate-to-severe AD: oral cyclosporine, subcutaneous injections of biologics (dupilumab, nemolizumab, tralokinumab), oral Janus kinase inhibitors (baricitinib, upadacitinib, abrocitinib), and phototherapy. In the revised guidelines, descriptions of five new drugs, namely, difamilast, nemolizumab, tralokinumab, upadacitinib, and abrocitinib, have been added. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 2","pages":"Pages 210-221"},"PeriodicalIF":6.2,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143477217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The gut–organ axis: Clinical aspects and immune mechanisms","authors":"Naoto Fukasawa ,&nbsp;Junya Tsunoda ,&nbsp;Shogo Sunaga ,&nbsp;Hiroki Kiyohara ,&nbsp;Nobuhiro Nakamoto ,&nbsp;Toshiaki Teratani ,&nbsp;Yohei Mikami ,&nbsp;Takanori Kanai","doi":"10.1016/j.alit.2025.01.004","DOIUrl":"10.1016/j.alit.2025.01.004","url":null,"abstract":"<div><div>The gut-brain axis exemplifies the bidirectional connection between the intestines and the brain, as evidenced by the impact of severe stress on gastrointestinal symptoms including abdominal pain and diarrhea, and conversely, the influence of abdominal discomfort on mood. Clinical observations support the notion of the gut–brain connection, including an increased prevalence of inflammatory bowel disease (IBD) in patients with depression and anxiety, as well as the association of changes in the gut microbiota with neurological disorders such as multiple sclerosis, Parkinson's disease, stroke and Alzheimer's disease. The gut and brain communicate via complex mechanisms involving inflammatory cytokines, immune cells, autonomic nerves, and gut microbiota, which contribute to the pathogenesis in certain gut and brain diseases. Two primary pathways mediate the bidirectional information exchange between the intestinal tract and the brain: signal transduction through bloodstream factors, such as bacterial metabolites and inflammatory cytokines, and neural pathways, such as neurotransmitters and inflammatory cytokines within the autonomic nervous system through the interaction between the nerve cells and beyond. In recent years, the basic mechanisms of the pathophysiology of the gut-brain axis have been gradually elucidated. Beyond the gut-brain interaction, emerging evidence suggests the influence of the gut extends to other organs, such as the liver and lungs, through intricate inter-organ communication pathways. An increasing number of reports on this clinical and basic cross-organ interactions underscore the potential for better understanding and novel therapeutic strategies targeting inter-organs networks. Further clarification of interactions between multiorgans premises transformative insights into cross-organ therapeutic strategies.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 2","pages":"Pages 197-209"},"PeriodicalIF":6.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive analysis of cytokine and chemokine gene expression in IgG4-related disease by spatial transcriptomics","authors":"Motohisa Yamamoto ,&nbsp;Ryuta Kamekura ,&nbsp;Masaaki Uehara ,&nbsp;Yuta Ichii ,&nbsp;Tomonao Tanaka ,&nbsp;Ken-ichi Takano","doi":"10.1016/j.alit.2024.12.010","DOIUrl":"10.1016/j.alit.2024.12.010","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 3","pages":"Pages 476-478"},"PeriodicalIF":6.2,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of systemic targeted therapies for atopic dermatitis in children: A systematic review and meta-analysis","authors":"Norio Kawamoto ,&nbsp;Hiroki Murai ,&nbsp;Kazutaka Nogami ,&nbsp;Takeshi Yamamoto ,&nbsp;Tomonobu Kikkawa ,&nbsp;Motoko Yasutomi-Sakai ,&nbsp;Kiwako Yamamoto-Hanada ,&nbsp;Masaki Futamura ,&nbsp;Yukihiro Ohya","doi":"10.1016/j.alit.2024.11.007","DOIUrl":"10.1016/j.alit.2024.11.007","url":null,"abstract":"<div><h3>Background</h3><div>In recent years, several targeted therapeutic options have become available for the management of atopic dermatitis in children. In this systematic review and meta-analysis, we assessed the efficacy and safety of systemic targeted therapies for atopic dermatitis in children.</div></div><div><h3>Methods</h3><div>A systematic review of literature available in CENTRAL, MEDLINE, Embase, and ICHUSHI databases until January 7, 2023, was performed. Randomized controlled trials of systemic targeted therapies (biologics and small molecules) on children aged 18 years or younger with atopic dermatitis were included. The primary outcomes were the eczema area and severity index (EASI) and adverse events. Other efficacy and safety outcomes were also used for meta-analysis and risk of bias analysis.</div></div><div><h3>Results</h3><div>We included 10 studies reported in 11 articles involving three agents (dupilumab, abrocitinib, and upadacitinib) and 1760 children. Systemic targeted therapies significantly improved eczema severity with an EASI-75 response (risk ratio, 2.99; 95 % confidence interval [CI], 2.66–3.37). However, systemic targeted therapies were associated with treatment-emergent adverse events (risk difference, 0.05; 95 % CI, 0.01–0.09), particularly among small molecules in subgroup analysis, while no such trend was observed with biologics. Systemic targeted therapy also significantly improved other efficacy outcomes, and no significant association was found in the other safety outcomes. There was no risk of bias in any of the outcomes.</div></div><div><h3>Conclusions</h3><div>Our findings indicate that systemic targeted therapies are effective and relatively safe for treating atopic dermatitis in children, although small molecules may pose a slightly higher risk of adverse events.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 3","pages":"Pages 424-434"},"PeriodicalIF":6.2,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143257049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effectiveness of mepolizumab in Japanese asthma patients with diverse backgrounds: Improvements in rhinosinusitis imaging (J-Real-Mepo)","authors":"Hiroyuki Nagase ,&nbsp;Konomi Kobayashi ,&nbsp;Makiko Toma-Hirano ,&nbsp;Maho Suzukawa ,&nbsp;Norihiro Harada ,&nbsp;Katsunori Masaki ,&nbsp;Yoshito Miyata ,&nbsp;Mayoko Tsuji ,&nbsp;Junko Terada-Hirashima ,&nbsp;Keiko Komatsuzaki ,&nbsp;Hitoshi Sasano ,&nbsp;Kenji Mizumura ,&nbsp;Ryoji Kagoya ,&nbsp;Yuya Shimizu ,&nbsp;Shintaro Yoshihara ,&nbsp;Norio Kihara ,&nbsp;Yasunari Miyazaki ,&nbsp;Toshiyuki Koya ,&nbsp;Naruhiko Sugihara ,&nbsp;Nobuhisa Ishikawa ,&nbsp;Yasuhiro Gon","doi":"10.1016/j.alit.2024.12.005","DOIUrl":"10.1016/j.alit.2024.12.005","url":null,"abstract":"<div><h3>Background</h3><div>Although randomized controlled trials (RCT) have demonstrated the efficacy of mepolizumab for asthma, they have excluded certain patient subgroups. To bridge the gap between RCT and real-world practice, the effectiveness of mepolizumab in a diverse population, including those potentially excluded from RCT, was assessed. Its effects on imaging findings and symptoms of chronic rhinosinusitis (CRS) with asthma were also assessed.</div></div><div><h3>Methods</h3><div>This retrospective observational study of patients in Japan (J-Real-Mepo: UMIN000045021) evaluated multiple endpoints and analyzed the relationship between clinical background and treatment outcomes.</div></div><div><h3>Results</h3><div>Mepolizumab significantly reduced exacerbations, improved Asthma Control Test (ACT) scores, and forced expiratory volume in 1 s, and reduced oral corticosteroid (OCS) dose, regardless of patient characteristics, including age, body mass index, smoking history, and comorbidities. Regarding RCT exclusion criteria, 29.4 % of patients had no history of exacerbations. Although 25.4 % of these patients required continuous OCS, the OCS dose was reduced similar to those with a history of exacerbations. Disease control and mepolizumab effectiveness in patients with a smoking history ≥10 pack-years was similar to that of never-smokers. Patients with eosinophil counts &lt;150/μL had lower ACT scores and higher OCS use compared with patients with eosinophilia and comparable effectiveness regarding exacerbation and OCS reduction. Significant improvements in Lund–Mackay scores and CRS symptoms were observed.</div></div><div><h3>Conclusions</h3><div>Mepolizumab effectiveness was demonstrated in a broad range of patients including those with RCT exclusion criteria, who had significant disease or OCS burden. These findings may explain the consistent results between RCT and real-world studies of mepolizumab.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 3","pages":"Pages 435-444"},"PeriodicalIF":6.2,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}